Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. theeoe

theEoE

A novel drug candidate for the treatment of Eosinophilic Esophagitis - an innovative solution for a significant unmet medical need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 theEoE project word cloud

Explore the words cloud of the theEoE project. It provides you a very rough idea of what is the project "theEoE" about.

environmental    treatment    approved    cells    thanks    integrity    barriers    bioavailability    causing    difficulty    persists    swallowing    discovery    patented    cellular    modifies    foods    uncontrolled    investing    ip    topical    proprietary    lower    eoe    inflammation    esophagus    payers    europe2020    eosinophilic    thelitetm    pain    physicians    vomiting    polarity    efficacy    accumulate    fly    candidate    smarter    patients    spending    line    epithelial    remodeling    disease    applies    company    blood    generating    inflammatory    pathologies    embryo    therapy    healthier    reduces    progression    platform    injury    sustainable    benefit    prioritized    local    possibly    diseases    manufacturing    clinical    necessarily    revolutionary    technologies    esophagitis    eosinophils    28    perfectly    white    modulation    innovation    compounds    drug    modulating    series    tissue    complications    elicited    fits    people    health    wellbeing    symptoms    theeoe    persistent    first    indications    occurs    allergens    nausea    points    promotion    regurgitation    time    toxicology    cure    risk    thelial    fewer    offers    decision    revenue    cell   

Project "theEoE" data sheet

The following table provides information about the project.

Coordinator		 THELIAL TECHNOLOGIES SA 

Organization address
address: PARQUE TECNOLOGICO DE CANTANHEDE, NUCLEO 4, LOTE 3
city: CANTANHEDE
postcode: 3060197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Portugal [PT]
 Project website http://www.thelial.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THELIAL TECHNOLOGIES SA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

Thelial Technologies, S.A. is a revenue generating drug discovery company that applies its unique, proprietary fly embryo-based technology to find new candidate compounds for the treatment of diseases that can be addressed by cell polarity modulation. By modulating cell polarity it is possible to specifically target a series of indications, where reduced integrity of epithelial cellular barriers is a key to pathologies. Using Thelial’s patented discovery platform theLiTETM the company has identified 28 candidate compounds, of which one – theEoE has been prioritized for further development based on toxicology, efficacy, bioavailability, IP and manufacturing decision points. theEoE will be the first approved product for treatment of Eosinophilic Esophagitis (EoE). EoE is an inflammatory disease of the esophagus elicited by foods and possibly environmental allergens. It occurs when a type of white blood cells, eosinophils, accumulate in the esophagus and persists, causing local injury and inflammation. Currently, there are no specific cure for the EoE, causing patients’ reduced wellbeing due to uncontrolled and persistent symptoms (e.g. high difficulty in swallowing, pain, nausea, regurgitation, and vomiting). Thelial offers a targeted topical treatment that reduces the clinical symptoms, modifies disease progression through tissue remodeling, and increases the duration of treatment response. These features will allow physicians, patients and payers to benefit from a revolutionary new treatment with fewer side-effects, and lower risk of health complications thanks to a better management of the disease over time. By promoting a first in line targeted therapy for EoE, Thelial’s innovation project perfectly fits the “Europe2020 challenges – for a healthier EU” 1) spending smarter but not necessarily more in sustainable health systems and 2) investing in people’s health, particularly through health-promotion programmes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THEEOE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THEEOE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More